Ipamorelin (10 mg vial)

Protocol Overview

Concise summary of the regimen.

Dosing & Reconstitution

One subcutaneous injection daily is the cadence throughout the course; ipamorelin is dosed every day rather than on a weekly schedule. Timing is ideally 30 to 60 minutes before bedtime on an empty stomach, so the injected pulse synergizes with natural nocturnal GH secretion, and the short half-life of about 1.5 to 2.5 hours makes a consistent daily hour more useful than a flexible one. At 10 mg/mL every dose in the protocol is a very small draw of 1 to 2.5 units, which is 0.01 to 0.025 mL, so insulin syringes marked to 30 or 50 units read far more accurately than a 100 unit barrel; a miscount of half a unit moves the dose by 50 mcg. Sites are rotated systematically across abdomen, thighs, and upper arms to reduce local irritation and avoid lipohypertrophy.

Results Timeline

Sequence described in the research record. Individual response varies.

• Weeks 1 to 2: the course opens at 100 mcg daily, which is 1 unit, while tolerance is assessed.
• Weeks 3 to 4: the daily dose steps up to 150 mcg, 1.5 units.
• Weeks 5 to 8: maintenance settles at 200 mcg daily, 2 units, the common middle-of-the-road dose.
• Weeks 9 to 12: the dose reaches 250 mcg daily, 2.5 units, with 16 weeks as an optional extension.
• After the course: a 2 to 4 week pause follows to resensitize receptors before any repeat cycle.

Reconstitution Steps

1. Draw 1.0 mL bacteriostatic water with a sterile syringe.
2. Inject slowly down the vial wall; avoid foaming.
3. Gently swirl until dissolved (do not shake).
4. Label with date and concentration; refrigerate at 2 to 8 °C, protected from light, and use within about 4 weeks. At 10 mg/mL, 1 unit = 0.01 mL » 100 mcg on a U-100 insulin syringe: 100 mcg = 1 unit, 150 mcg = 1.5 units, 200 mcg = 2 units, 250 mcg = 2.5 units.

Storage Instructions

Proper storage preserves peptide quality.

• Lyophilized: store at 2 to 8 °C for short-term storage or minus 20 °C for long-term storage, in dry, dark conditions.
• Reconstituted: refrigerate at 2 to 8 °C, protected from light, and use within about 4 weeks when reconstituted with bacteriostatic water.

• For longer storage, freeze aliquots at minus 20 °C and avoid repeated freeze-thaw cycles.
• Allow vials to reach room temperature before opening to reduce condensation uptake.

Supplies Needed

Planning is based on an 8 to 16 week daily course with gradual titration, which runs from 0.7 mg per week at the 100 mcg starting dose to 1.75 mg per week at 250 mcg.

Peptide Vials (Ipamorelin, 10 mg vial):

• An 8 week course totals about 9.1 mg, 12 weeks about 16.1 mg, and 16 weeks about 23.1 mg, which the master sheet plans as roughly 2 vials, 2 to 3 vials, and 3 vials of the 10 mg presentation; reconstituted peptide is used within about 4 weeks, so that in-use window, rather than the raw milligrams, is what drives the vial count upward.

Insulin Syringes (U-100):

• Per week: 7 syringes, one per day (U-100, with 30 or 50 unit markings preferred at these small volumes).
• 8 weeks: 56 syringes. 12 weeks: 84 syringes. 16 weeks: 112 syringes.

Bacteriostatic Water (10 mL bottles):

• Each 10 mg vial takes 1.0 mL, so one 10 mL bottle of bacteriostatic water covers 10 vials, well beyond what a full 16 week course requires.

Alcohol Swabs:

• Per injection: 2 swabs, one for the vial stopper and one for the site, so 14 swabs per week.
• 8 weeks: 112 swabs (two 100 count boxes). 12 weeks: 168 swabs. 16 weeks: 224 swabs (three 100 count boxes).

Important Notes

Practical considerations for consistency and safety.

• Use a new sterile insulin syringe for each injection and dispose of it in a sharps container; reconstituted vials are used within about 4 weeks, so vial timing is matched to the dosing block.
• Rotate injection sites across abdomen, thighs, and upper arms to reduce local irritation, inject slowly, and wait a few seconds before withdrawing the needle.
• Document the daily dose and site rotation to maintain consistency across a course that runs 8 to 16 weeks.
• Ipamorelin has a short half-life of about 1.5 to 2.5 hours, so a consistent daily injection time matters more here than it does for long-acting compounds.
• At 10 mg/mL every dose sits between 1 and 2.5 units, which is 0.01 to 0.025 mL; a 30 unit or 50 unit syringe is the practical choice, since half a unit on this concentration is 50 mcg.
• Regulatory Note: ipamorelin is not an approved drug for human therapeutic use and is supplied for research purposes only, not for human consumption.

How This Works

Ipamorelin binds to the growth hormone secretagogue receptor (GHSR-1a) and stimulates the pituitary gland to release endogenous growth hormone in a pulsatile manner. Unlike earlier growth hormone releasing peptides, ipamorelin is highly selective and does not significantly stimulate ACTH, cortisol, or prolactin release at effective doses. After subcutaneous injection, GH levels peak within approximately 40 minutes and return to baseline by 2 to 3 hours. This short-acting pulsatile effect makes it suitable for once-daily administration in support of physiological GH patterns. Animal studies have shown that even chronic daily exposure did not significantly desensitize GH release mechanisms, though cycling is still recommended as a precautionary measure. Ipamorelin has also demonstrated pro-motility effects in the gastrointestinal tract via GHSR-1a receptors.

Benefits & Side Effects

Observations from the published record.

• Supports increases in lean body mass and improvements in recovery through GH-mediated anabolic processes.
• Enhances fat metabolism and supports favorable body composition changes over time.
• High selectivity for GH release with minimal impact on other hormones, notably ACTH, cortisol, and prolactin.
• May support improved gastric motility and digestive function through GHSR-1a receptors in the gut.
• Generally well tolerated, with a low incidence of side effects at typical doses.
• Possible side effects: occasional mild injection-site reactions such as redness and swelling, with very rare reports of water retention or increased hunger.

Lifestyle Factors

Complementary strategies for best outcomes.

• A balanced, protein-adequate diet supports the muscle synthesis and recovery this protocol is meant to assist.
• Combining resistance training with cardiovascular exercise maximizes the anabolic and metabolic response.
• Seven to nine hours of quality sleep nightly matters here in particular, since GH naturally peaks during deep sleep phases.
• Managing stress helps, because chronic stress and elevated cortisol can blunt the GH response; injecting on an empty stomach, with no food for 2 to 3 hours before and 30 to 60 minutes after, also supports GH release.

Injection Technique

General subcutaneous guidance from clinical best-practice resources.

1. Clean the vial stopper and skin with alcohol; allow to dry.
2. Pinch a skinfold; insert the needle at 45 to 90 degrees into subcutaneous tissue.
3. Do not aspirate for subcutaneous injections; inject slowly and steadily.
4. Wait 5 to 10 seconds before withdrawing; dispose of syringe in sharps container.
5. Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.

References

Source citations for further reading.

1. Raun K et al. Ipamorelin, the first selective growth hormone secretagogue (European Journal of Endocrinology, 1998).
2. Pharmacokinetic-pharmacodynamic modeling of ipamorelin in human volunteers (Pharmaceutical Research, 1999).
3. Three-week chronic in vivo ipamorelin treatment: no desensitization of GH release (European Journal of Anatomy, 2002).
4. Ipamorelin for postoperative ileus in bowel resection patients (Int J Colorectal Disease, 2014).